 2007 |
|
 December
10 |
Option Agreement Concluded Between Maruishi Pharmaceutical Co., Ltd.
and AnGes MG, Inc.
- Implementing Exploratory Research on Candidate Compound
for Novel Drug for Treatment of Skin Diseases - |
| November
15 |
Announcement of a Contract Concluded by Three Companies on
R&D of “Drug-Eluting Balloon Catheter” for Prevention of
Vascular Restenosis |
| November
15 |
Announcement of Joint R&D Contract Termination between
Goodman Co., Ltd. and AnGes MG, Inc. |
| November
13 |
AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe- |
| October
29 |
Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan |
| August
31 |
A Research-and-Development Project of GenomIdea Inc.,a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector - |
| August
29 |
Basic Patent of HGF Gene Therapy is Granted in Korea |
| August
13 |
AnGes MG, Inc. Submits BLA for Naglazyme in Japan |
| July
11 |
Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent) |
| July
9 |
Completion of Targeted Number of Patient Enrollment in Phase II Clinical Trial of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis in Japan |
| June
20 |
Announcement on Acquisition of First-Class Drug Marketing Business License |
| June
14 |
Announcement of Results of Phase III Clinical Trials
of HGF Gene Therapy in Japan |
| June
7 |
Announcement Regarding the Official Designation of Naglazyme as an Orphan Drug |
| February
15 |
Toyobo and GenomIdea Forms Business Alliance
- Product Launch of Master Cell Bank for Drug Manufacturing - |
| February
7 |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Intractable and Diabetes-related Peripheral Arterial Occlusive Diseases - |
| January
22 |
AnGes MG, Inc. Announces Marketing and Distribution Agreement with BioMarin
Pharmaceutical Inc. for Naglazyme in Japan |
| January
11 |
The Clinical Trial of HGF Plasmid in Japan has Achieved Necessary
Number of Subject Enrollment for Efficacy Analysis |
| January
10 |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Cardiomyopathy - |
| January
5 |
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7® as First-line Therapy for Metastatic
Melanoma |
